New drug combo shows promise in shrinking High-Risk liver tumors
NCT ID NCT05194293
First seen Oct 31, 2025 · Last updated Jun 13, 2026 · Updated 39 times
Summary
This phase 2 trial tests whether combining regorafenib (a drug that blocks cancer cell growth) with durvalumab (an immunotherapy that helps the immune system attack cancer) can shrink tumors in people with high-risk liver cancer. The study includes 4 adults with early-stage liver cancer who are eligible for surgery. The goal is to see if this treatment can reduce tumor size and improve surgical outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III HEPATOCELLULAR CARCINOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, 35233, United States
Conditions
Explore the condition pages connected to this study.